Next-generation ALK inhibitors excel after crizotinib failure
Next-generation ALK inhibitors excel after crizo
Targeting angiogenesis can prolong life
Targeting angiogenesis can prolong life Ande
EGFR-targeted therapy: at the right time in the right patient
EGFR-targeted therapy: at the right time in the
No phase III benefit with selumetinib in KRAS-mutant NSCLC
No phase III benefit with selumetinib in KRAS-mu
SCLC: genomic alterations pave the way to targeted approaches
SCLC: genomic alterations pave the way to target
Rare driver mutations: encouraging results in small patient populations
Rare driver mutations: encouraging results in sm
Preface – ESMO 2016
Preface – ESMO 2016 Silvia Novello, MD, PhD,
Rare driver mutations: BRAF- and HER2-mutant NSCLC
Rare driver mutations: BRAF- and HER2-mutant NSC
ALK-positive NSCLC: updates on crizotinib and alectinib
ALK-positive NSCLC: updates on crizotinib and al
Characteristics and outcomes for SCLC arising from transformation
Characteristics and outcomes for SCLC arising fr
